IGF2BP3 and neoplasm: There was almost no statistically significant difference in IGF2BP3 expression in PAAD patient samples among different tumor grades, disease stages, lymph node metastasis, race, gender, age, drinking habits, diabetes status, and pancreatitis status (Additional files 4B-I, 6).